ArticleThe Australasian journal of dermatology2025
Retrospective Review on Safety and Efficacy of Combination Biologic Therapy for Psoriasis.
Article in The Australasian journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical case series: Emergence of psoriatic arthritis during biologic IL-23 pathway inhibition therapy for psoriasis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited data on the use of dual or combination biologic therapy in dermatological patients, particularly in psoriasis or with other coexisting dermatological conditions. However, this may be necessary for a small proportion of patients.
methodsWe conducted a retrospective review of 46 patients treated with dual or combination biologic therapy at a single dermatology practice in Sydney, Australia. The patient cohort consisted of 44 patients with psoriasis, 1 patient with hidradenitis suppurativa and 1 patient with a combination of hidradenitis suppurativa and psoriasis.
resultsOf 46 patients receiving a combination of biological agents, only 1 experienced an adverse effect that did not require cessation of therapy.
conclusionThe use of combination biologic therapy may be an option for psoriasis patients with recalcitrant disease, in particular for those with concomitant psoriatic arthritis or other dermatological conditions. However, further studies are warranted to evaluate the efficacy, safety and health economics of this treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.